Supplementary Figure 2 from The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Abstract
mSTAT6D419N Eµ-Myc tumors have no difference in number or proportion of CD4+ or CD8+ T-cells at early and late disease as compared to mSTAT6WT Eµ-Myc tumors.
Fields of Study & Subjects
Lymphoma Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
Chemokine receptors and signaling
Publication details
- Publication date
- 4 March 2026
- Language
- EN